HopeStage
Back to overview

ADHD studies

Topics
More filters

ADHD

Attention-deficit/hyperactivity disorder (ADHD) involves persistent difficulties with attention, impulsivity or restlessness that can affect everyday life.

1811studies shown
Showing 1,429-1,440 of 1,811
Drug study icon
CompletedNCT03662763

Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity

Official study title

Phase 3,Double Blind,Placebo-controlled,Multicentre,Randomised-withdrawal,Long-term Maintenance of Efficacy&Safety Study of Extended-release Guanfacine Hydrochloride in Children/Adolescents Aged 6-17 With ADHD

This study has finished and is no longer accepting participants.

In Maastricht
ADHDMedication studyAges 6–17
Countries
Netherlands
Sponsor
Maastricht University Medical Center
Device study icon
TerminatedNCT05736458

Network Control TMS fMRI

Official study title

Network Control and Functional Context: Mechanisms for TMS Response

This study ended early.

In Philadelphia
ADHDDevice studyAges 18–28
Countries
United States
Sponsor
University of Pennsylvania
Drug study icon
CompletedNCT07253441

A study to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels

Official study title

A Multiple-arm, Phase 1, Open-label Trial to Determine Dose Strength Equivalence and Effect of Food on To-Be-Marketed Centanafadine QD XR Capsules, Bioequivalence Between Clinical and To-Be-Marketed QD XR Capsules and Relative Bioavailability of To-Be-Marketed QD XR Capsules to SR Tablets in Healthy Adults

This study has finished and is no longer accepting participants.

Multiple locations, including Lenexa
ADHDMedication studyAges 18–55
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Drug study icon
CompletedNCT00664703

Effectiveness of Lobeline in Treating Symptoms of ADHD in Adult Patients

Official study title

A Double-Blind, Double-Dummy, Placebo-Controlled, Dose Ranging Study of 7.5, 15, and 30 mg of Sublingual Lobeline in Adult ADHD Patients

This study has finished and is no longer accepting participants.

In Lexington
ADHDMedication studyAges 21–45
Countries
United States
Sponsor
Yaupon Therapeutics

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.